NCT06275360View on ClinicalTrials.gov

Repositioning Immunotherapy in VetArans With Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

March 31, 2030

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Nivolumab

Carboplatin, paclitaxel, and nivolumab for three cycles (for squamous cell lung cancer) or Carboplatin, pemetrexed, and nivolumab for three cycles (for lung adenocarcinoma) Followed by radiotherapy (60 Gy in 30 fractions) Followed by adjuvant nivolumab (six cycles)

Trial Locations (7)

90073-1003

NOT_YET_RECRUITING

VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles

06516-2770

RECRUITING

VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven

48105-2303

RECRUITING

VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor

68105-1850

NOT_YET_RECRUITING

Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha

27705-3875

NOT_YET_RECRUITING

Durham VA Medical Center, Durham, NC, Durham

44106-1702

NOT_YET_RECRUITING

Louis Stokes VA Medical Center, Cleveland, OH, Cleveland

23249-0001

NOT_YET_RECRUITING

Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond

All Listed Sponsors
lead

VA Office of Research and Development

FED